1. Horowitz, DP, Sharma, CS, Connolly, E, et al. Secretory carcinoma of the breast: results from the survival, epidemiology and end results database. Breast 2012; 21(3): 350–353.
Google Scholar | Crossref | Medline2. Lee, SG, Jung, SP, Lee, HY, et al. Secretory breast carcinoma: a report of three cases and a review of the literature. Oncol Lett 2014; 8(2): 683–686.
Google Scholar | Crossref | Medline3. Fisher, B, Anderson, S, Bryant, J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16): 1233–1241.
Google Scholar | Crossref | Medline | ISI4. Haviland, JS, Owen, JR, Dewar, JA, et al. The UK standardisation of breast radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013; 14(11): 1086–1094.
Google Scholar | Crossref | Medline | ISI5. Whelan, TJ, Pignol, JP, Levine, MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362(6): 513–520.
Google Scholar | Crossref | Medline | ISI6. Smith, BD, Bellon, JR, Blitzblau, R, et al. Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Rad Oncol 2018; 8(3): 145–152.
Google Scholar | Crossref | Medline7. Gold, HT, Do, HT, Dick, AW. Correlates and effect of suboptimal radiotherapy in women with ductal carcinoma in situ or early invasive breast cancer. Cancer 2008; 113(11): 3108–3115.
Google Scholar | Crossref | Medline8. Tognon, C, Knezevich, SR, Huntsman, D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002; 2: 367–376.
Google Scholar | Crossref | Medline | ISI9. Li, D, Xiao, X, Yang, W, et al. Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature. Mod Pathol 2012; 25: 567–575.
Google Scholar | Crossref | Medline10. Yorozuya, K, Takahashi, E, Kousaka, J, et al. A case of estrogen receptor positive secretory carcinoma in a 9-year-old girl with ETV6-NTRK3 fusion gene. Jpn J Clin Oncol 2012; 42(3): 208–211.
Google Scholar | Crossref | Medline11. Vasudev, P, Onuma, K. Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression. Arch Pathol Lab Med 2011; 135(12): 1606–1610.
Google Scholar | Crossref | Medline12. Grabellus, F, Worm, K, Willruth, A, et al. ETV6–NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual. Breast 2005; 14: 71–74.
Google Scholar | Crossref | Medline13. Conlon, N, Sadri, N, Corben, AD, et al. Acinic cell carcinoma of breast: morphologic and immunohistochemical review of a rare breast cancer subtype. Hum Pathol 2016; 51: 16–24.
Google Scholar | Crossref | Medline14. Reis-Filho, JS, Natrajan, R, Vatcheva, R, et al. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using etv6'split apart’ probes. Histopathology 2008; 52: 840–846.
Google Scholar | Crossref | Medline | ISI15. Bane, AL, Whelan, TJ, Pond, GR, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol 2014; 25(5): 992–998.
Google Scholar | Crossref | Medline